Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19

Next Previous
Search
Trial Profile

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients With COVID-19

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 14 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bemnifosbuvir (Primary)
  • Indications COVID 2019 infections
  • Focus Registrational; Therapeutic Use
  • Acronyms SUNRISE-3
  • Sponsors Atea Pharmaceuticals

    • Most Recent Events

    • 07 Nov 2024 According to an Atea pharmaceuticals media release, Given the trial results and the changing landscape of the pandemic, Atea will not pursue a regulatory pathway forward for bemnifosbuvir for COVID-19.
    • 13 Sep 2024 Primary endpoint (Proportion of subjects hospitalized for any cause or died due to any cause) has not been met as per results presented in the Atea pharmaceuticals Media Release.
    • 13 Sep 2024 Results presented in the Atea pharmaceuticals Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top